Fei Yuan, Qiu Yuxuan, Xing Zhichao, Zhao Wanjun, Su Anping, Zhu Jingqiang
Department of Thyroid & Parathyroid Surgery, West China Hospital, Sichuan University, NO. 37 Guo Xue Xiang, 610041, Chengdu, Sichuan, PR China.
Endocrine. 2020 Nov;70(2):426-434. doi: 10.1007/s12020-020-02429-8. Epub 2020 Jul 28.
To explore the effects of initial radioiodine therapy on parathyroid function among postoperative papillary thyroid cancer (PTC) patients.
Postoperative PTC patients who were admitted in our department from April 2018 to April 2019 were recruited. Patients were divided into two groups: Group A, who underwent surgery and initial radioiodine therapy in our hospital, and Group B, who did not receive radioiodine therapy after surgery. The levels of serum calcium, magnesium, phosphorus, parathyroid hormone (PTH), and 25 hydroxyvitamin D3 were collected. Data were analyzed by SPSS 25.0.
A total of 252 patients were included. Between the two groups, no significant difference of PTH in 6th, 9th, and 12th month was found during postoperative follow-up (p = 0.493, p = 0.202, p = 0.814). No significant difference of PTH was found after stratifying Group A according to I dosage (p = 0.751 for 6th month after operation, p = 0.130 for 9th month after operation, p = 0.683 for 12th month after operation), interval time between surgery and radioiodine therapy (p = 0.522 for 3rd day after I therapy, p = 0.184 for 9th month after operation, p = 0.311 for 12th month after operation), and ratio of parathyroid autotransplantation (p = 0.545 for 3rd day after I therapy, p = 0.485 for 6th month after operation, p = 0.201 for 9th month after operation, p = 0.146 for 12th month after operation).
Initial radioiodine therapy following PTC surgery had no significant adverse effect on parathyroid function in the short term. However, physicians should inform patients of possible risks of abnormal parathyroid function prior to RAI therapy, and parathyroid function was periodically reviewed after RAI therapy.
探讨首次放射性碘治疗对甲状腺乳头状癌（PTC）术后患者甲状旁腺功能的影响。
选取2018年4月至2019年4月在我科住院的PTC术后患者。患者分为两组：A组在我院接受手术及首次放射性碘治疗，B组术后未接受放射性碘治疗。收集血清钙、镁、磷、甲状旁腺激素（PTH）及25羟维生素D3水平。数据采用SPSS 25.0进行分析。
共纳入252例患者。术后随访期间，两组在第6、9和12个月时PTH水平无显著差异（p = 0.493，p = 0.202，p = 0.814）。根据I剂量对A组进行分层后，PTH水平无显著差异（术后第6个月p = 0.751，术后第9个月p = 0.130，术后第12个月p = 0.683），手术与放射性碘治疗之间的间隔时间（I治疗后第3天p = 0.522，术后第9个月p = 0.184，术后第12个月p = 0.311），以及甲状旁腺自体移植比例（I治疗后第3天p = 0.545，术后第6个月p = 0.485，术后第9个月p = 0.201，术后第12个月p = 0.146）。
PTC手术后首次放射性碘治疗在短期内对甲状旁腺功能无显著不良影响。然而，医生应在放射性碘治疗前告知患者甲状旁腺功能异常的可能风险，且在放射性碘治疗后定期复查甲状旁腺功能。
